BMP therapies are becoming promising alternatives to autografts, which are currently the gold standard for chronic bone defects, but remain limited by low availability as well as donor site pain and inflammation.[16, 44] Dysregulation of BMP signaling has been shown to contribute to a number of pathological processes, including cancer and ectopic bone formation.[45, 46] Thus, understanding how BMP‐2 regulates differentiation and manipulating BMP‐2 signaling are both critically important for both clinical regenerative medicine and the rational design of growth factor‐doped biomaterials. The gene discussed is BMP2; the disease is cancer.